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Abstract
Haloperidol is an effective antipsychotic drug for treatment of schizophrenia, but prolonged use 
can lead to debilitating side effects. To better understand the effects of long-term administration, 
we measured global metabolic changes in mouse brain following 3 mg/kg/day haloperidol for 28 
days. These conditions lead to movement-related side effects in mice akin to those observed in 
patients after prolonged use. Brain tissue was collected following microwave tissue fixation to 
arrest metabolism and extracted metabolites were assessed using both liquid and gas 
chromatography mass spectrometry (MS). Over 300 unique compounds were identified across MS 
platforms. Haloperidol was found to be present in all test samples and not in controls, indicating 
experimental validity. Twenty-one compounds differed significantly between test and control 
groups at the p < 0.05 level. Top compounds were robust to analytical method, also being 
identified via partial least squares discriminant analysis. Four compounds (sphinganine, N-
acetylornithine, leucine and adenosine diphosphate) survived correction for multiple testing in a 
non-parametric analysis using false discovery rate threshold < 0.1. Pathway analysis of nominally 
significant compounds (p < 0.05) revealed significant findings for sphingolipid metabolism (p = 
0.02) and protein biosynthesis (p = 0.03). Altered sphingolipid metabolism is suggestive of 
disruptions to myelin. This interpretation is supported by our observation of elevated N-
acetylaspartylglutamate in the haloperidol-treated mice (p = 0.004), a marker previously 
associated with demyelination. This study further demonstrates the utility of murine 
neurochemical metabolomics as a method to advance understanding of CNS drug effects.
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Antipsychotic drugs are central to the treatment of schizophrenia, a serious and debilitating 
mental disorder characterized by delusions, hallucinations, social withdrawal and cognitive 
deficits (van Os and Kapur, 2009). Haloperidol was among the first antipsychotics and was 
widely hailed as a breakthrough upon its introduction in the 1950s (Lopez-Munoz and 
Alamo, 2009). Since then, haloperidol has been used extensively in psychiatry and its 
effectiveness is well established (Adams et al., 2013). However, it is now realized that 
haloperidol can lead to severe, debilitating and sometimes irreversible side effects 
(Rosebush and Mazurek, 1999; Gao et al., 2008).
Among the side effects of haloperidol, the risk for extrapyramidal symptoms (EPS) is 
perhaps the most salient. In a meta-analysis of antipsychotic clinical trials, haloperidol had 
the highest risk of EPS among all 15 antipsychotic drugs studied (Leucht et al., 2013). EPS 
are a complex and potentially heterogeneous set of symptoms, characterized by involuntary 
movement and loss of motor control. These include parkinsonism, akathisia and tardive 
dyskinesia (TD), which can sometimes persist long after drug treatment has ended (Marsden 
and Jenner, 1980). While haloperidol has a high risk for EPS, more modern antipsychotic 
drugs are not without risk for these side effects (Peluso et al., 2012). EPS therefore represent 
an ongoing issue with antipsychotic drug treatment. Understanding the biological 
mechanisms that lead to haloperidol-induced EPS could conceivably guide future drug 
design. If we can identify the pathways leading to EPS, new candidate compounds could be 
evaluated for their toxicity relative to activation of these pathways.
Research into the biology of EPS has traditionally focused on dopaminergic 
neurotransmission (Meltzer and Stahl, 1976). Specifically, antipsychotics are hypothesized 
to produce EPS due to blockade of dopamine D2 receptors in the striatum, which acts as an 
interface between higher brain function in the cortex and motor control in the basal ganglia 
(Meltzer and Stahl, 1976; Glazer, 2000). While dopamine receptor blockade plays an 
established role in antipsychotic action (Meltzer, 2013), it cannot explain some critical 
features of EPS, such as the persistence of symptoms after drug treatment has ended. TD, for 
example, develops in approximately one third of patients undergoing long-term treatment 
with "typical" first generation antipsychotics, including haloperidol, and may be irreversible 
in up to half of such cases (Soares-Weiser and Fernandez, 2007). The biological basis of TD 
is essentially unknown (Crowley et al., 2012a), suggesting that new directions in EPS 
research may be warranted. In this respect, the use of massively-parallel, discovery-oriented 
"omics" technologies could be fruitful. One such potentially powerful tool for understanding 
the global biological consequences of drug administration is metabolomics (Clayton et al., 
2006; Kaddurah-Daouk et al., 2008; Patti et al., 2012).
When using metabolomic approaches to understand the consequences of CNS drugs, 
researchers have generally either utilized accessible human body fluids such as blood, or 
have obtained tissue from laboratory model organisms, in particular rodents. To the best of 
our knowledge, only one previous study has used metabolomics methods to examine the 
biochemical effects of antipsychotics in the rodent brain. Specifically, McLoughlin et al. 
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(2009) examined the effects of several different classes of psychotropic drugs, including 
haloperidol, in rat brain using NMR. However, drawbacks of their study included the 
relative insensitivity of NMR relative to MS analysis and the relatively small number of 
compounds reported (n=15).
We have previously employed methods to assay the neurochemical metabolic effects of 
CNS drugs in mice (McClay et al., 2013), measuring over 300 unique compounds using a 
mix of MS methods, and considered that application of these methods to haloperidol could 
shed light on biochemical mechanisms. A particular advantage of our strategy is the use of 
focused beam microwave irradiation (FBMI) to instantaneously and permanently denature 
all enzymes in the brain at time of sacrifice (de Graaf et al., 2009). In a high-intensity 
microwave pulse lasting only milliseconds, brain metabolism is arrested completely and 
metabolites are preserved in the pre-sacrifice state (Ikarashi et al., 1985; Login and Dvorak, 
1994). Considering EPS specifically, an established rodent model of TD has been developed 
to study the phenotype (Turrone et al., 2002). In this model, chronic administration of 
antipsychotics, including haloperidol, leads to vacuous chewing movements similar to those 
observed in patients with TD (Crowley et al., 2012a). Therefore, in the present study, we 
report untargeted MS-based metabolomic analysis of murine brain tissue following exposure 
to long-term haloperidol administration at doses previously demonstrated to produce 
behavioral symptoms that model EPS in patients.
Methods
Subjects
Eight week old male C57BL/6J mice were obtained from the Jackson Laboratory (Bar 
Harbor, ME). Mice were allowed to acclimate to the vivarium (AAALAC-accredited) for 1 
week prior to testing and were housed up to four per cage. Food (7012 Teklad LM-485 
Sterilizable Diet, Harlan Laboratories, Indianapolis, Indiana) and water were available ad 
libitum under a 12-h/12-h light/dark cycle (lights on at 0700–1,900 h) with all testing 
occurring during the light phase. All procedures were approved by the Institutional Animal 
Care and Use Committee of Virginia Commonwealth University.
Drug administration
Our aim was to achieve steady-state concentrations of haloperidol that mimic clinical doses 
in patients (10–50 nM or 3.75–19 ng/ml) (Hsin-tung and Simpson, 2000). Previous work 
(Crowley et al., 2012a; Crowley et al., 2012b) indicated that 3.0 mg/kg/day haloperidol 
delivered via continuous 60-day slow release subcutaneous pellets (Innovative Research of 
America, Sarasota, FL) yielded plasma haloperidol concentrations in mice in the 10– 50 nM 
range with lower variation as compared to minipumps, repeated injections or oral 
administration. Furthermore, this dose and delivery method has been previously 
demonstrated to produce vacuous chewing movements in C57BL/6J mice that peaked 
around four weeks and persisted for over one year, long after drug administration ended 
(Crowley et al., 2012a). Therefore, for our metabolomics experiments, eleven animals 
received haloperidol pellets delivering 3.0 mg/kg/day, while ten control animals received 
placebo pellets containing the same matrix materials but no drug. Pellets were implanted 
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subcutaneously, centrally above the scapulae, under isoflurane anesthesia and the incision 
sealed with VetBond (3M, St. Paul, MN). After recovery, animals were returned to the 
standard housing conditions outlined above.
Sample preparation
After 28 days, animals were sacrificed via focused beam microwave irradiation (FBMI), 
using a 10 kW microwave tissue fixation system (Muromachi TMW-4012C, Tokyo, Japan). 
Brain tissue was collected by dissection immediately after fixation, followed by snap 
freezing in liquid nitrogen. Samples were stored at -80 °C prior to overnight shipment on dry 
ice to the metabolomics facility (Metabolon, Research Triangle Park, NC). Brain tissue was 
homogenized using a GenoGrinder (OPS Diagnostics, Lebanon, NJ) and extracted into two 
fractions using proprietary solvents (Metabolon, Research Triangle Park, NC). The first 
fraction was for analysis via liquid chromatography mass spectrometry (LC/MS), while the 
second was for analysis via gas chromatography mass spectrometry (GC/MS). A TurboVap 
(Zymark, Hopkinton, MA) was used to quickly remove organic solvent before samples were 
frozen and vacuum dried in preparation for loading. Aliquots from each experimental 
sample were pooled and these “matrix” samples were injected throughout the platform day 
run and served as technical replicates. In this manner, variability in quantitation of the 
experimental samples was monitored.
Liquid chromatography mass spectometry (LC/MS, LC/MS2): The LC/MS component of 
our metabolomics approach was previously described in detail by (Evans et al., 2009). 
Briefly, the LC/MS platform used a Waters (Milford, MA) Acquity ultra performance liquid 
chromatography (UPLC) and a Thermo-Finnigan (Thermo Fisher, Waltham, MA) LTQ 
mass spectrometer, consisting of an electrospray ionization (ESI) source and linear ion-trap 
(LIT) mass analyzer. The sample extract was split into two aliquots, dried, then reconstituted 
in acidic or basic LC-compatible solvents, each of which contain eleven injection standards 
at fixed concentrations. One aliquot was analyzed using acidic positive ion optimized 
conditions and the other using basic negative ion optimized conditions in two independent 
injections using separate dedicated columns. Extracts reconstituted in acidic conditions were 
gradient eluted using water and methanol, both containing 0.1% formic acid, while the basic 
extracts, which also use water/methanol, contained 6.5 mM ammonium bicarbonate. The 
MS analysis was alternated between MS and data-dependent MS2 scans using dynamic 
exclusion (McClay et al., 2013).
The LC/MS mass accurate portion of the platform used a Surveyor high performance liquid 
chromatography (HPLC) and a Thermo-Finnigan LTQ-FT mass spectrometer, with a linear 
ion-trap front end and a Fourier transform ion cyclotron resonance mass spectrometer 
backend. For ion counts more than 2 million, an accurate mass measurement was performed. 
These were made on the parent ion as well as fragments and the typical mass error was 
under 5 ppm. Ions with counts under two million required more effort to characterize. 
Fragmentation spectra (MS/MS) were typically generated in data dependent manner, but 
where necessary, targeted MS/MS was employed, such as in the case of lower level signals 
(McClay et al., 2013).
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Gas chromatography / Mass Spectroscopy (GC/MS)
A previous implementation of the GC/MS platform was described by (Ohta et al., 2009). 
Samples undergoing GC/MS analysis were redried under vacuum for at least 24 hours prior 
to being derivatized under dried nitrogen using bistrimethyl-silyl-triflouroacetamide 
(BSTFA). The GC column was 5% phenyl and the temperature ramp was 40° to 300° C in 
16 minutes. Samples were analyzed on a Thermo-Finnigan Trace DSQ fast-scanning single-
quadrupole mass spectrometer using electron impact ionization.
Data pre-processing
Proprietary in-house software (Metabolon, Research Triangle Park, NC) was used to 
perform detection and integration of MS peaks as described previously (Evans et al., 2009). 
Briefly, extracted ion chromatograms were binned by mass, baseline noise was determined, 
peaks areas were calculated, and peak thresholds including minimum height, signal-to-noise, 
width, symmetry, and area were applied. MS peaks passing the above threshold criteria were 
grouped based on peak apex retention times. Deconvolution and identification of correlated 
ion features was carried out as described previously (Dehaven et al., 2010), with correlated 
ion features from multiple platforms belonging to a given biochemical organized into a 
single ion group. This ion group is then used to represent that metabolite in statistical 
analyses. Specific biochemicals were identified by comparison to library entries of purified 
standards (approximately 1500 for the GC and LC platforms combined). Haloperidol was 
added to the compound library so that it could be identified for validation purposes.
Following deconvolution and library matching, each identified compound was represented 
by a single, uncorrected quantitative variable. The following steps were taken to process the 
data prior to statistical analysis: 1) metabolites with >50% missing values were dropped, 2) 
for the remaining metabolites, missing values were imputed with half of the minimum 
positive value of each variable in the original data under the assumption that they were 
below the limits of detection, 3) metabolites with low variance, specifically the 10% with 
the lowest standard deviations, were dropped from further analysis, and 4) data 
normalization was carried out via autoscaling, whereby each variable was mean-centered 
and divided by the standard deviation.
Statistical Analysis
All analysis was carried out using the MetaboAnalyst package, version 2.0 (Xia and 
Wishart, 2011; Xia et al., 2012). After data quality control and normalization as described 
above, we first tested for significant differences in the levels of each compound between the 
haloperidol and control groups using Student's t-test. We then used Statistical Analysis of 
Microarrays (SAM) (Tusher et al., 2001), a non-parametric method implemented for 
metabolomics in MetaboAnalyst, to calculate significance and correct for multiple testing 
using a false discovery rate (FDR) threshold of 0.1 (van den Oord and Sullivan, 2003). We 
also implemented multivariate analysis in the form of partial least squares discriminant 
analysis (PLS-DA), a supervised discriminatory method, to inspect the differences between 
the two experimental groups. Validity of the PLS-DA model was assessed using cross-
validation methods, as recommended by (Bijlsma et al., 2006). Finally, overrepresentation 
analysis (ORA) was used to test the set of nominally significant metabolites (p < 0.05) from 
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our univariate analysis for enrichment within known biological pathways. A hypergeometric 
test was used to evaluate if our metabolite set was represented more than expected by chance 
within canonical biological pathways.
Results
Animals receiving haloperidol tolerated the drug well and all implants remained intact at 28 
days. Metabolomic analysis of brain tissue detected 302 unique compounds across both MS 
platforms. Of these, 201 were identified with confidence while the rest were consistently 
detected entities that could not be identified because no matching entries were present in our 
compound library. However, these unidentified compounds were included in our analyses 
under the assumption that any showing significant associations with haloperidol exposure 
could be followed-up in subsequent experiments, if necessary. As a validation measure, 
haloperidol was added to our library and investigated in our metabolomic analysis. We 
observed detectable levels of haloperidol in all test samples and in no control samples. This 
confirmed experimental validity as it shows the drug was present in the tissue of interest 
(brain) at the time of sampling. Previous work (Crowley et al., 2012a) showed that the dose 
and delivery method used (3 mg/kg/day) led to blood concentrations comparable to clinical 
doses in humans.
Our initial analysis aimed to detect the compounds that differed the most between the 
haloperidol-treated animals and controls. After data quality control and normalization, we 
performed t-tests for all compounds and identified 21 significant findings at p < 0.05 (Table 
1). Of these 12 were up-regulated and 9 were down-regulated in the haloperidol-treated 
animals relative to controls. The most significant up-regulated compounds were N-acetyl-
aspartyl-glutamate (NAAG), a common peptide neurotransmitter compound in the 
mammalian brain, and 2-stearoyl glycerophosphocholine, a lysophosphatidylcholine and 
component of biological membranes. The most significant down-regulated compounds were 
leucine, a common amino acid, and sphinganine, an important sphingolipid metabolite and 
intermediate in the synthesis of ceramide. Several energy-related compounds, such as ADP 
and glucose, were also altered in the haloperidol-treated animals.
Considering we used a significance threshold of p < 0.05, with the expectation of one false 
positive finding (type I error) for every 20 tests, and that we tested 302 unique compounds, 
the expected number of type I errors was 15.1. We exceeded this by detecting 21 significant 
effects. However, to more formally address the issue of multiple testing, we used SAM 
(statistical analysis of microarrays). This non-parametric test was designed for use in high-
dimensional biological experiments with limited numbers of samples and uses permutations 
to obtain empirical levels of significance. The results from SAM are shown in Figure 1. We 
observed four compounds that were significant at a false discovery rate (FDR) threshold of 
0.068. We typically use an FDR threshold of 0.1 to declare findings significant as this 
provides an optimum balance between detecting effects and controlling type I errors (van 
den Oord and Sullivan, 2003). The four significant compounds, starting with the most 
significant, were leucine, sphinganaine, ADP and N-acetylornithine, all of which were 
down-regulated in the haloperidol-treated animals. NAAG, the most up-regulated 
compound, just failed to reach significance in this analysis.
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In addition to analysis of individual compounds, a common multivariate analysis technique 
employed in metabolomic studies is partial least squares discriminant analysis (PLS-DA). 
PLS-DA projects the data into a low-dimensional space that maximizes the separation 
between experimental groups using a small number of latent variables. Figure 2A shows a 
clear separation of the two treatment groups using this method. Both 10-fold cross-
validation and leave-one-out cross-validation (LOOCV) methods indicated a four dimension 
model was optimal in explaining the maximum amount of variation using the cross-
validated sum of squares. The most important compounds in the PLS-DA projection, i.e. 
those that matter most in discriminating between haloperidol-treated animals and controls, 
are shown in Figure 2B. There was very substantial agreement between the compounds 
indicated by PLS-DA and those observed in the univariate analysis. Specifically, the top six 
compounds were leucine, NAAG, sphinganine, ADP, N-acetylornithine and 2-stearoyl 
glycerophosphocholine. These compounds, as a group, were noticeably distinct from the 
next most relevant compounds (Figure 2B).
To test for functional themes in our results, we performed a pathway analysis on significant 
(p < 0.05) compounds in our univariate analysis. Starting with the list of 21 compounds, we 
removed recurrent unidentified compounds as these cannot be assigned to pathways. We 
also removed basic energy metabolites, such as glucose and ADP, because of their 
ubiquitous nature. This left 14 compounds, of which 11 could be mapped to the compound 
database. These were entered into pathway analysis in the MetaboAnalyst package and the 
results are shown in Table 2. The most significant pathway was sphingolipid metabolism, 
reiterating the significant finding with sphinganine in all previous analyses, but also 
including sphingosine that was nominally significant in the univariate analysis.
Discussion
Our study involved the untargeted analysis of 302 unique metabolites to compare global 
neurochemistry of mice treated with chronic haloperidol for 28 days versus controls. 
Advantages of our study included 1) a high degree of experimental control, with genetically 
homogenous mice housed in constant conditions, 2) a proven drug delivery method that 
produces blood haloperidol concentrations in mice similar to clinical doses in humans, 3) a 
dose and duration of haloperidol treatment previously shown to produce movement-related 
side effects in C57BL/6 mice that serves as a model of human EPS, 4) FBMI to denature 
brain enzymes and instantly arrest metabolism at time of sacrifice, and 5) a multi-platform 
metabolomics strategy that yielded data on over 300 compounds.
Several analytical methods converged on key compounds that were significantly altered in 
haloperidol-treated animals versus controls. Our overall top finding was leucine. While an 
important amino acid, it is somewhat ubiquitous in metabolism and therefore does not give 
any substantial, specific insights into the action of haloperidol. Several of our other top 
findings were similarly ubiquitous, particularly energy metabolites such as ADP. These 
compounds are recognized to be highly variable from sample to sample, and therefore it can 
be difficult to obtain reliable findings. Nevertheless, recent studies have shown that 
molecular pathways associated with brain energy metabolism are altered by antipsychotic 
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treatments in human patients (Ma et al., 2009). Thus, our energy-related findings are broadly 
consistent with human studies of antipsychotic drugs.
Other top findings in our study included sphinganine and N-acetylornithine, both of which 
passed FDR control in our SAM analysis. N-acetylornithine is a minor component of 
deproteinized mammalian blood (Armstrong, 1979) and is an intermediate in arginine 
metabolism. It has been linked to chronic kidney disease and suggested as a possible 
biomarker for kidney function in humans (Suhre et al., 2011). However, no previous study 
has linked N-acetylornithine to antipsychotics, nor is there a characterized role for this 
compound in the CNS. Therefore, a causal relationship between decreased N-acetylornithine 
and haloperidol exposure, as observed here, is difficult to speculate upon. On the other hand, 
our finding with sphinganine suggests very specific CNS-related mechanisms affected by 
haloperidol.
Decreased sphinganine was observed in the haloperidol-treated animals relative to controls. 
Furthermore, our pathway analysis revealed sphingolipid metabolism as the top result. The 
compounds contributing to this pathway analysis finding were sphinganine and sphingosine. 
These are both sphingolipid metabolites that may function as second messengers or 
regulators of signal transduction that affect events ranging from apoptosis to regulation of 
the cell cycle (Hoekstra et al., 2003). They form part of the broader sphingolipid class of 
compounds, which are one of the three major classes of membrane lipids in eukaryotic cells 
(Levy and Futerman, 2010). Sphingolipids have important roles in cell recognition, 
neurotransmission and nervous system cell signaling (Hoekstra et al., 2003). Specifically, 
sphingosine is an 18-carbon aliphatic amino alcohol that is phosphorylated to shingosine-1-
phosphate, a potent signaling lipid with activity in the CNS (Okada et al., 2009; Martin and 
Sospedra, 2014). Furthermore, sphingosine is converted to ceramide via ceramide 
synthetase, in addition to being a breakdown product of ceramide via alkaline ceramidase, 
while sphinganine is an intermediate in ceramide synthesis (Figure 3). Another compound 
among our nominally significant findings was phosphocholine. The addition of a 
phosphocholine residue from CDP-choline to ceramide via ceramide 
cholinephosphotransferase produces sphingomyelin, the major component of the myelin 
sheath that surrounds and insulates nerve cell axons (Slotte, 2013) (Figure 3). Taken 
together, our findings appear to converge on sphingomyelin.
In our data, sphingosine, sphinganine and phosphocholine were all depleted in the 
haloperidol treated mice. Considering previous rodent studies of antipsychotic effects on 
CNS metabolites, the most notable study to date was published by McLoughlin et al. (2009). 
In this study, the authors investigated several drugs, including haloperidol. Differences in 
their approach from that used in our current study included 1) the use of rats rather mice, 2) 
1.0 mg/kg/day haloperidol for 21 days administered orally rather than 3.0 mg/kg/day for 28 
days via subcutaneous implant, and 3) the use of NMR to study 15 unique compounds, 
rather than MS to study over 300. Despite these differences, phosphocholine was among the 
15 compounds they measured and they also observed diminished levels of this metabolite in 
haloperidol-treated animals. Thus, our phosphocholine finding is essentially a replication of 
that by McLoughlin et al. (2009). While the other sphingolipids identified our study, 
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sphinganine and sphingosine, were not measured by McLoughlin et al., the replication of 
phosphocholine adds further validity to our findings.
As outlined, our findings with sphingolipids and phosphocholine appear to converge on 
sphingomyelin. This could suggest a disruption to myelin following long-term haloperidol 
treatment. In support of this interpretation, our most significant up-regulated compound in 
the haloperidol-treated animals was N-acetyl-aspartyl-glutamate (NAAG). NAAG is a 
peptide neurotransmitter that is synthesized in neurons and present at high concentrations in 
the CNS. It modulates glutamatergic neurotransmission and may have roles in synaptic 
plasticity and neuroprotection (Benarroch, 2008). Impaired NAAG signaling has been 
implicated in schizophrenia and some studies have suggested NAAG plays a role in 
antipsychotic drug mechanisms of action (Ghose et al., 2009; Olszewski et al., 2012; Jessen 
et al., 2013). Of particular relevance to our current study, elevated NAAG has been 
associated with hypomyelination disorders such as Canavan's disease and Pelizaeus-
Merzbacher disease (PMD) (Kolodziejczyk et al., 2009). Symptoms of these disorders 
include a diminished motor control. Elevated NAAG has also been observed in a mouse 
model of PMD (Takanashi et al., 2012). The model involves a myelin synthesis-deficient 
mouse, which has a loss of motor control as a characteristic phenotype. In other human 
studies, demyelination has been directly linked to extrapyramidal movement abnormalities 
in cases not involving antipsychotics (van der Knaap et al., 2007).
Our group previously conducted a genome-wide association study of EPS in 738 patients 
with schizophrenia, most of whom were treated with atypical antipsychotics (Aberg et al., 
2010). One of our genome-wide significant findings was with genetic variants in ZNF202, a 
gene encoding a transcriptional repressor. ZNF202 controls expression of PLP1, which 
encodes a major protein in myelin. Mutations in PLP1 cause PMD and indeed this gene is 
deleted in the myelin synthesis-deficient mouse model of PMD mentioned above. Together, 
these observations could indicate that haloperidol-induced EPS may result, at least in part, 
from demyelination. There is a lack of focus on this mechanism in the literature with respect 
to antipsychotic-induced EPS. If targeted studies can confirm this hypothesis, future drug 
studies could examine the demyelination potential of new candidate antipsychotic 
compounds to limit EPS in patients. It should be emphasized that while haloperidol has one 
of the highest incidences of EPS of any antipsychotic (Leucht et al., 2013), more recent 
antipsychotics are not free from EPS (Peluso et al., 2012). Any improvement in our ability 
to limit these side effects could have substantial clinical benefit.
Our study provides new data on the CNS effects of chronic haloperidol administration, that 
suggests a role for demyelination in the pathophysiology of EPS. Expanding these methods 
to investigate other antipsychotics could be a fruitful avenue to identify novel biological 
mechanisms of efficacy and unwanted side-effects.
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Statistical Analysis of Microarrays (SAM), as implemented in MetaboAnalyst and applied to 
our metabolomics data. The plot shows observed (y-axis) compared to expected (x-axis) 
values of the d(i) statistic. This represents the ratio of difference in metabolite levels 
between groups to the variation observed in the data for that metabolite. Thresholds (delta = 
0.6) were adjusted to control the FDR < 0.1. Four compounds, all down-regulated in 
haloperidol-treated animals, passed FDR control at threshold = 0.068, as indicated in the 
plot.
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Three dimensional plot of the top 3 components in PLS-DA of our metabolomics data, 
showing clear separation of the groups by metabolite profiles. "Haldol" (triangles) indicates 
the haloperidol-treated animals, while "Veh" (crosses) are the controls.
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Variables of importance in projection (VIP) scores for the most relevant metabolites in PLS-
DA. The panel to the right indicates relative effect direction in the two groups.
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Functional relationships between selected top metabolite findings. Compounds measured in 
our study are color-coded to illustrate their significance levels in the haloperidol (haldol) 
versus control analysis. Effect directions in the haloperidol-treated animals are illustrated by 
arrows to the right of measured compounds. Ceramide synthesis takes place in the 
endoplasmic reticulum, while synthesis of sphingomyelin occurs in the golgi body (see 
Small molecular Pathway Database SMPDB00034 sphingolipid metabolism (Frolkis et al., 
2010)). Sphingomyelin is the major component of the insulating myelin sheath that 
surrounds axons. Demyelination has been previously associated with elevated N-acetyl-
aspartyl-glutamate (NAAG) levels, also observed in our study.
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Table 1
All nominally significant (p < 0.05) metabolite findings in a comparison of brain tissue from animals 
undergoing chronic haloperidol treatment versus controls. Compounds names "Y-…" indicate recurrent, 
unique compounds that could not be assigned an identity because no corresponding entry existed in our 
library. ChEBI is the compound ID from the Chemical Entities of Biological Interest database from the 
European Bioinformatics Institute (Hastings et al., 2013). P-values are from t-tests conducted using the 
"MetaboAnalyst" software package. Effect direction is given for the haloperidol-treated animals versus 
controls.
Compound ChEBI ID p-value Haloperidol effectdirection
leucine 15603 0.00281 −
N-acetyl-aspartyl-glutamate (NAAG) 73688 0.00375 +
sphinganine 16566 0.00378 −
adenosine 5'-diphosphate (ADP) 16761 0.00388 −
N-acetylornithine 16543 0.00466 −
2-stearoyl glycerophosphocholine 76076 0.00558 +
glutaroyl carnitine 82952 0.01214 −
Y-12422 (recurrent unidentified compound) n/a 0.01476 +
Glucose 17234 0.01684 +
guanosine 5'- diphosphate (GDP) 17552 0.01868 −
Homoserine 15699 0.01948 +
phosphocholine 18132 0.02618 −
homocarnosine 28050 0.03059 +
sphingosine 16393 0.03410 −
5-methylthioadenosine (MTA) 17509 0.03452 +
Y-12421(recurrent unidentified compound) n/a 0.03499 +
tyrosine 17895 0.04282 +
adenosine 5'-monophosphate (AMP) 16027 0.04310 −
24(S)-hydroxycholesterol 34310 0.04607 +
oleate (18:1n9) 30823 0.04737 +
fructose 1,6-diphosphate 78682 0.04756 +
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Table 2
Pathway analysis of nominally significant compounds. "Total" gives the number of compounds in the 
reference pathway, "expected" is the number of hits expected by chance, while "hits" is the observed number 
in our data.
Pathway total expected Hits p-value
SPHINGOLIPID METABOLISM 15 0.2 2 0.0154
PROTEIN BIOSYNTHESIS 19 0.253 2 0.0244
METHIONINE METABOLISM 24 0.32 2 0.038
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